Shares of Mednax, Inc (NYSE:MD) have received an average rating of “Hold” from the fifteen analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $53.70.
Several research firms have issued reports on MD. Piper Jaffray Companies began coverage on shares of Mednax in a report on Wednesday. They set an “overweight” rating and a $58.00 price objective on the stock. Jefferies Group reaffirmed a “hold” rating and set a $44.00 price objective on shares of Mednax in a report on Friday, November 3rd. KeyCorp raised shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 price objective on the stock in a report on Sunday, September 17th. Citigroup decreased their price objective on shares of Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Finally, BMO Capital Markets began coverage on shares of Mednax in a report on Monday, October 16th. They set a “market perform” rating and a $46.00 price objective on the stock.
In other Mednax news, Director Cesar L. Alvarez sold 10,668 shares of Mednax stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the transaction, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the transaction, the insider now directly owns 35,569 shares in the company, valued at $1,834,649.02. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.
Mednax (MD) traded down $0.10 on Thursday, reaching $51.58. 1,146,300 shares of the company’s stock traded hands, compared to its average volume of 1,093,425. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $4,840.10, a P/E ratio of 15.80, a price-to-earnings-growth ratio of 1.67 and a beta of 0.40. Mednax has a fifty-two week low of $40.56 and a fifty-two week high of $72.13.
Mednax (NYSE:MD) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.87. The business had revenue of $868.95 million for the quarter, compared to the consensus estimate of $864.78 million. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The company’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the firm posted $1.09 earnings per share. sell-side analysts expect that Mednax will post 3.1 earnings per share for the current fiscal year.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.